###begin article-title 0
###xml 21 27 <span type="species:ncbi:10090">Murine</span>
The Role of SRC-1 in Murine Prostate Carcinogenesis Is Nonessential due to a Possible Compensation of SRC-3/AIB1 Overexpression
###end article-title 0
###begin p 1
Conflict of Interest: The authors have declared that no conflict of interest exists.
###end p 1
###begin p 2
###xml 378 383 378 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 388 393 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 708 715 708 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 732 737 732 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 990 993 990 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 985 993 985 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 1006 1008 1006 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 1426 1431 1426 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 1474 1479 1474 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 1579 1584 1579 1584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 1638 1641 1638 1641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 1633 1641 1633 1641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 424 429 <span type="species:ncbi:9606">human</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
###xml 752 756 <span type="species:ncbi:10090">mice</span>
###xml 801 805 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 856 860 <span type="species:ncbi:10090">mice</span>
###xml 949 953 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 994 998 <span type="species:ncbi:10090">mice</span>
###xml 1009 1013 <span type="species:ncbi:10090">mice</span>
###xml 1104 1108 <span type="species:ncbi:10090">mice</span>
###xml 1190 1195 <span type="species:ncbi:10090">mouse</span>
###xml 1358 1362 <span type="species:ncbi:10090">mice</span>
###xml 1642 1646 <span type="species:ncbi:10090">mice</span>
The androgen and androgen receptor (AR)-regulated gene expression plays important roles in normal prostate and prostate cancer development, and AR transcriptional control of genes is mediated by transcriptional coactivators, including the three members of the steroid receptor coactivator (SRC) family, SRC-1 (NCOA1), SRC-2 (TIF2/GRIP1/NCOA2) and SRC-3 (AIB1, ACTR/RAC3/NCOA3). SRC-1 and SRC-3 are overexpressed in multiple human endocrine cancers and knockdown of either one of them in prostate cancer cell lines impedes cellular proliferation. Knockout of SRC-3 in mice suppresses the progression of spontaneous prostate carcinogenesis. In this study, we investigated SRC-1 contribution to prostate cancer in vivo by deleting the SRC-1 gene in TRAMP mice, which contain the probasin promoter-driven SV40 T/t antigen transgene. In assessing tumor mass of mice at various ages, we found that initiation and progression of prostate cancer induced by SV40 T/t antigens were unaltered in SRC-1-/- mice versus WT mice. Primary tumor histology and metastasis to distant lymph nodes were also similar in these mice at all time points assessed. These results demonstrate that the role of SRC-1 in mouse prostate carcinogenesis is nonessential and different from the essential contribution of SRC-3 that is required for prostate cancer progression and metastasis in mice. Interestingly, we observed that during prostate tumorigenesis SRC-1 expression was relatively constant, while SRC-3 expression was significantly elevated. Therefore, the loss of SRC-1 function may be compensated by SRC-3 overexpression during prostate tumorigenesis in SRC-1-/- mice.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 61 64 <span type="species:ncbi:9606">men</span>
Prostate cancer is the most common malignancy among American men and second leading cause of cancer death 1. Early in their development, prostate tumors require androgen stimulation for growth and survival. Therein they respond to androgen deprivation therapy. Following remission, however, tumors frequently recur in an androgen-independent form refractory to current treatment modalities 2. Understanding the development and progression of prostate cancer through androgen-dependent and independent stages is essential for devising novel targeted therapeutic strategies.
###end p 4
###begin p 5
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1040 1045 1040 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 1175 1176 1175 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1190 1195 1190 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-2</italic>
###xml 1274 1275 1274 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1277 1278 1277 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1297 1300 1297 1300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 1292 1300 1292 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3<sup>-/-</sup></italic>
###xml 1410 1411 1410 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1413 1414 1413 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 922 926 <span type="species:ncbi:10090">mice</span>
###xml 1049 1053 <span type="species:ncbi:10090">mice</span>
###xml 1269 1273 <span type="species:ncbi:10090">mice</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
The androgen receptor (AR) signaling pathway is involved in development and progression of prostate cancer 3. Androgen receptor is a member of the nuclear receptor superfamily, a collection of proteins with hormone-activated transcriptional activities. Transcriptional control by nuclear receptors depends not only on the presence and concentration of appropriate hormone but also on regulation by coactivator molecules. Coactivators associate with hormone-bound receptors at the gene site and recruit general transcription machinery. Therefore, coactivator expression level and activity may profoundly alter the transcriptional activities of nuclear receptors 4, 5. The best-characterized coactivators comprise the steroid receptor coactivator (SRC) family. Its three members are 160-kDa proteins termed SRC-1 (NCOA1), SRC-2 (TIF2/GRIP1/NCOA2) and SRC-3 (AIB1/p/CIP/RAC3/ACTR/TRAM-1/NCOA3). Extensive studies in knockout mice demonstrate involvement of the SRC family in regulating normal development and physiology. Genetic disruption of SRC-1 in mice results in partial steroid hormone resistance in reproductive organs such as uterus, prostate, testis, and mammary gland 5. Deletion of SRC-2 causes reproductive impairment and hypofertility in both male and female mice 6, 7. SRC-3 null (SRC-3-/-) mice exhibit somatic growth retardation, female reproductive dysfunction and mammary gland growth reduction 8, 9. Therein, SRC family members have critical roles in development and maintenance of normal tissues.
###end p 5
###begin p 6
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 132 135 132 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 126 135 126 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3 <sup>-/-</sup></italic>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 448 453 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 592 595 592 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 587 595 587 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3<sup>-/-</sup></italic>
###xml 749 751 749 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 764 772 764 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1062 1064 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 353 357 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 399 404 <span type="species:ncbi:10090">mouse</span>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
Several groups, including our own, have demonstrated important roles for SRC proteins in multiple cancers 10-15. We exploited SRC-3 -/- mice to determine that SRC-3 deficiency suppresses mammary gland tumor development induced either by oncogenes or chemical carcinogens 11, 12, 16. We identified an association between SRC-3 and prostate cancer in the SV40-induced transgenic adenocarcinoma of the mouse prostate (TRAMP) model, noting increase in SRC-3 expression in prostatic luminal epithelial cells during tumorigenesis. To further investigate the relationship, we crossed TRAMP and SRC-3-/- mice. Remarkably, prostate cancer progression observed in these bigenic animals was markedly delayed and much more differentiated than those observed in WT/TRAMP mice. In vitro studies demonstrating the requirement of SRC-3 for prostate cancer cell proliferation and survival confers our findings 10, 14. In addition, SRC-3 directly regulates transcription of matrix metalloproteinases, MMP-2, MMP-9 and MMP-13, to potentiate cancer cell invasion and metastasis 15, 16.
###end p 6
###begin p 7
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 380 388 380 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
SRC-1 has also been linked to prostate cancer. A clinical study showed increased SRC-1 protein in hormone-refractory prostate tumors compared with benign prostatic hyperplasia or androgen-dependent tumors 17. A second study showed increased SRC-1 expression in localized androgen dependent prostate tumors correlates with increased metastases to distant lymph nodes 18. Moreover, in vitro analyses demonstrate that SRC-1 knockdown represses the activation of AR target genes and reduces AR-dependent cellular proliferation 18.
###end p 7
###begin p 8
###xml 60 69 60 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> in vivo </italic>
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 137 145 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 344 346 344 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 415 418 415 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 410 418 410 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3<sup>-/-</sup></italic>
###xml 463 471 463 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 537 542 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 585 587 585 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 603 606 603 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 598 607 598 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup>/</italic>
###xml 116 121 <span type="species:ncbi:10090">mouse</span>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
In the current study, we investigate the role of SRC-1 in an in vivo model of prostate cancer. We created a bigenic mouse model in which SRC-1-/- mice were crossed with TRAMP mice. Surprisingly, inactivation of SRC-1 did not inhibit prostate cancer initiation and progression, as tumors in bigenic mice were morphologically similar to those of WT/TRAMP mice. These results are at odds with our findings in the SRC-3-/- TRAMP bigenic and also contradict published in vitro and clinical findings. Interestingly, we observed an increase in SRC-3 expression in the prostate tumors of both WT/TRAMP and SRC-1-/-/TRAMP mice. Therefore, SRC-3 may compensate for the absent SRC-1 in promoting prostate tumorigenesis in this model. In conclusion, our analysis of prostate carcinogenesis in TRAMP model with a SRC-1 null background demonstrates that SRC-1 is not an essential coactivator to drive prostate cancer initiation and progression.
###end p 8
###begin title 9
MATERIALS AND METHODS
###end title 9
###begin p 10
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mice. </bold>
###xml 11 14 11 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 6 14 6 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 58 59 58 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 295 298 295 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 290 298 290 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 316 319 316 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 311 319 311 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 461 464 461 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 456 464 456 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 544 547 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 539 547 539 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 573 576 573 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 568 576 568 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>+/+</sup></italic>
###xml 577 579 577 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 994 995 994 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 587 591 <span type="species:ncbi:10090">mice</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
###xml 816 820 <span type="species:ncbi:10090">mice</span>
###xml 950 954 <span type="species:ncbi:10090">mice</span>
Mice. SRC-1-/- mice were initially generated as described 5, and subsequently backcrossed into a C57BL/6J strain background. TRAMP mice with 50% C57BL/6J and 50% 129SvEV genetic contribution and harboring the Probasin-SV40 T/t transgene were produced as previously reported 19. To generate SRC-1-/-/TRAMP mice, SRC-1-/- mice in C57BL/6J genetic background were crossed with 50% C57BL/6J-50% 129SvEV TRAMP mice. The offspring were backcrossed with C57BL/6J SRC-1-/- mice three times to generate 93.75% C57BL/6J-6.25% 129SvEV (experimental) SRC-1-/-/TRAMP and (control) SRC-1+/+(WT)/TRAMP mice. This breeding strategy ensured all experimental mice were hemizygous for the TRAMP transgene. Genotyping was performed via PCR-based screening assay on DNA extracted from ear tip biopsy by proteinase K digestion. For TRAMP mice, primer sequences were 5'-CCGGTCGACCGGAAGCTTCCACAAGTGCATTTA (forward) and 5'-CTCCTTTCAAGACCTAGAAGGTCCA (reverse). SRC-1 knockout mice were genotyped as described previously 5.
###end p 10
###begin p 11
###xml 0 34 0 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tissue examination and Histology. </bold>
###xml 554 555 554 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 1089 1091 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Tissue examination and Histology. TRAMP and bigenic mice were weighed, anesthetized and sacrificed at 8, 12, 18, 24 and 30 weeks of age. All major organs were inspected for evidence of tumors, while lymph nodes were assessed for metastases. The entire genitourinary (GU) tract, consisting of the bladder, urethra, seminal vesicles, ampullary gland, and prostate, was excised and dissected under low power microscope. The wet weights of the GU tract, seminal vesicles, and prostate were recorded. Tissues were fixed in 10% buffered formalin for 12 hr at 4oC, dehydrated in sequentially increasing ethanol concentrations, processed and embedded in paraffin blocks. Sections of 5 mum thickness were stained with hematoxylin and eosin (H&E), and examined under a light microscope. Histopathology was determined according to the GEM grading classification scheme in which prostatic intraepithelial neoplasia (PIN), well-differentiated adenocarcinoma (WDA), moderately-differentiated adenocarcinoma (MDA) and poorly-differentiated adenoarcinoma (PDA) are qualitatively and quantitatively scored 20.
###end p 11
###begin p 12
###xml 0 22 0 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Immnuohistochemistry. </bold>
###xml 465 466 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sup>
###xml 503 508 <span type="species:ncbi:10090">Mouse</span>
###xml 582 586 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 605 609 <span type="species:ncbi:9925">goat</span>
###xml 649 655 <span type="species:ncbi:9986">rabbit</span>
###xml 742 748 <span type="species:ncbi:9986">rabbit</span>
###xml 754 759 <span type="species:ncbi:10090">mouse</span>
###xml 771 776 <span type="species:ncbi:9796">horse</span>
###xml 782 786 <span type="species:ncbi:9925">goat</span>
###xml 801 805 <span type="species:ncbi:9925">goat</span>
###xml 811 817 <span type="species:ncbi:9986">rabbit</span>
Immnuohistochemistry. All immunohistochemical staining was performed on 5 mum de-parafinized sections. Antigen retrieval was carried out by incubating the slides in 0.01 M citric acid buffer (pH 6.0) using microwave method. Slides were then cooled and washed successively with PBS and deionized water. Next, endogenous peroxidase activity was inactivated by incubation in methanol containing 3% hydrogen peroxide. Sections were subsequently incubated overnight at 4oC with following primary antibodies: Mouse monoclonal anti-T antigen (BD Transduction Laboratory) (for detection of SV40 large T-antigen), goat polyclonal anti-SRC-1 (Santa Cruz) and rabbit polyclonal anti-SRC-3 (Cell Signaling) antibodies. Biotinylated secondary antibodies, rabbit anti-mouse for TRAMP, horse anti-goat for SRC-1 and goat anti-rabbit for SRC-3 were used, and were each diluted 1:600. The Avidin Biotin Complex kit (Vector Laboratories) was used for chromophore-mediated detection.
###end p 12
###begin p 13
###xml 0 24 0 24 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Immunoblotting analysis.</bold>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 193 199 <span type="species:ncbi:9986">rabbit</span>
###xml 239 245 <span type="species:ncbi:9986">rabbit</span>
###xml 339 344 <span type="species:ncbi:9796">Horse</span>
###xml 345 351 <span type="species:ncbi:3726">radish</span>
###xml 381 385 <span type="species:ncbi:9925">goat</span>
###xml 392 398 <span type="species:ncbi:9986">rabbit</span>
Immunoblotting analysis. Prostate samples designated for Western blot analysis were lysed in RIPA buffer and prepared as described 13. The following primary antibodies were used for detection: rabbit polyclonal anti-SRC-1 (Santa Cruz) and rabbit polyclonal anti-AIB1 (SRC-3) (gift from Dr. R. Wu, Baylor College of Medicine, Houston, TX). Horse radish peroxydase (HRP)-conjugated (goat) anti-rabbit secondary antibodies were used.
###end p 13
###begin title 14
RESULTS
###end title 14
###begin title 15
Loss of SRC-1 does not suppress prostate cancer tumorigenesis
###end title 15
###begin p 16
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 68 76 68 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 158 160 158 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 424 427 424 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 419 427 419 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 475 477 475 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 495 496 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 594 596 594 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 612 615 612 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 607 615 607 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 713 714 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 839 841 839 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 857 860 857 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 852 860 852 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 906 907 906 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 1162 1165 1162 1165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 1157 1165 1157 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 1180 1182 1180 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 1234 1237 1234 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 1229 1237 1229 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 1252 1254 1252 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 1390 1392 1390 1392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 1408 1411 1408 1411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 1403 1411 1403 1411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 1544 1547 1544 1547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 1539 1547 1539 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 1558 1560 1558 1560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 434 438 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 867 871 <span type="species:ncbi:10090">mice</span>
###xml 1189 1193 <span type="species:ncbi:10090">mice</span>
###xml 1261 1265 <span type="species:ncbi:10090">mice</span>
###xml 1418 1422 <span type="species:ncbi:10090">mice</span>
###xml 1567 1571 <span type="species:ncbi:10090">mice</span>
To study the contribution of SRC-1 to prostate cancer, we generated SRC-1-/-/TRAMP mice and compared formation and progression of genitourinary tumors versus WT/TRAMP mice. We monitored tumor growth in each genotype, collecting tissue samples at 8, 12, 18, 24, and 30 weeks of age. At each time point, we assessed total body weight and individual weights of GU tract, prostate and seminal vesicles. At all time points, SRC-1-/-/TRAMP mice had slightly lower body weight than WT/TRAMP mice (Fig. 1A). Relative GU tract weight (normalized to body weight) increased progressively with age in both WT/TRAMP and SRC-1-/-/TRAMP mice. No statistically significant difference was observed between the two genotypes (Fig. 1B). Similarly, relative weights of prostate and seminal vesicle (each normalized to body weight) were also unchanged between WT/TRAMP and SRC-1-/-/TRAMP mice at each time point assessed (Fig. 1, C and D). Upon sacrifice, we inspected the GU tract under low power dissecting microscope and collected all identifiable tumors. No tumors were grossly visible in either genotype at the 8, 12 and 18-week time points. At the 24-week time point, 6/8 SRC-1-/-/TRAMP and 7/9 WT/TRAMP mice developed tumors. At 30 weeks, 9/9 SRC-1-/-/TRAMP and 7/7 WT/TRAMP mice had large GU tract tumors. Tumors collected at both the 24 and 30-week time points had similar gross morphology between the WT/TRAMP and SRC-1-/-/TRAMP mice. Therefore, gross anatomical assessment suggests prostate tumorigenesis and local cancer progression are similar in SRC-1-/-/TRAMP and WT/TRAMP mice.
###end p 16
###begin p 17
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 137 140 137 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 132 140 132 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 151 153 151 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 413 415 412 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 488 491 487 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 483 491 482 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 573 574 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 680 683 679 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 675 683 674 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 694 696 693 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 703 707 <span type="species:ncbi:10090">mice</span>
In order to ascertain the impact of SRC-1 deletion on tumor morphology, we performed histopathological assessment of prostates from SRC-1-/-/TRAMP and WT/TRAMP mice at 8, 12, 18, 24, and 30-week time points. 5 mum H&E-stained sections from mice of each genotype were subjected to morphological (GEM) analysis for cancer progression, taking into account relative abundance of PIN, WDA, MDA, and PDA tissues. While WT/TRAMP appeared at 12 weeks to show a subtly advanced cancer versus SRC-1-/-/TRAMP, both genotypes had similar morphology at all subsequent time points (Fig. 2). Therefore, the histological analysis further indicates similar prostate tumor progression between SRC-1-/-/TRAMP and WT/TRAMP mice.
###end p 17
###begin title 18
Ablation of SRC-1 does not inhibit prostate cancer metastasis
###end title 18
###begin p 19
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 228 231 228 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 223 231 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 245 247 245 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 625 628 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 620 628 620 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 639 641 639 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 797 798 797 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 882 885 882 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 877 885 877 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 896 898 896 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 1067 1068 1067 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
###xml 905 909 <span type="species:ncbi:10090">mice</span>
###xml 980 984 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Clinical studies demonstrated that enhanced SRC-1 expression is associated with increased local invasiveness, metastatsis, and fatal disease progression 18. Therefore, we evaluated metastatic capacity of prostate tumors in SRC-1-/-/TRAMP versus WT/TRAMP mice. Specifically, we assessed periaortic lymph nodes, lungs, and liver since these organs are common sites of metastasis in the TRAMP model 19. Following sacrifice, periaortic lymph nodes were weighed and observed under the dissecting microscope. The relative (normalized to body weight) weight of the periaortic lymph nodes increased as a function of age in both SRC-1-/-/TRAMP and WT/TRAMP mice. Neither the overall rate of weight increase nor weights at individual time points were significantly different between the two genotypes (Fig. 3A). Moreover, we detected metastatic lesions in periaortic lymph nodes of both SRC-1-/-/TRAMP and WT/TRAMP mice. H&E staining of lymph node tissue confirmed presence of tumors while SV40 immunohistochmistry demonstrated tumors were prostate-originated metastases (Fig. 3B). Metastases were evident at weeks of age in both genotypes and we observed no significant difference in the number or morphology of these lesions at any subsequent time point. In sum, no significant difference was observed in lymph node size or metastatic tumor morphology between the two genotypes at any time between 8 and 36 weeks of age.
###end p 19
###begin title 20
SRC-1 expression is relatively consistent throughout the stages of prostate cancer progression
###end title 20
###begin p 21
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 672 673 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 698 703 698 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 762 763 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 794 799 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
To check the SRC-1 expression patterns in TRAMP mouse prostate tissues, SRC-1 immunohistochemistry was performed. SRC-1 was found to be expressed in luminal epithelial cells and tumor cells of the prostate tissue and the expression was consistent with moderate level throughout the different stages of tumor progression (Fig. 4A). SRC-1 null prostate tissues were used as negative control (Fig. 4A). We also carried out immunoblotting analysis to obtain semi-quantitative SRC-1 level in TRAMP mice. SRC-1 level did not increase progressively as a function of age and prostate cancer progression. In fact, SRC-1 protein level decreased between 18 and 24 weeks of age (Fig. 4C). Protein lysates from SRC-1-null TRAMP prostates were used as negative controls (Fig. 4C). These results suggest that SRC-1 is not overexpressed during prostate carcinogenesis in mice.
###end p 21
###begin title 22
###xml 81 84 81 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 76 84 76 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 95 97 95 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 14 18 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Evaluation of SV40 T antigen and SRC-3 expression in the prostate tissue of SRC-1-/-/TRAMP and WT/TRAMP mice
###end title 22
###begin p 23
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 68 76 68 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 87 89 87 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 326 331 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 50 54 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 96 101 <span type="species:ncbi:10090">mouse</span>
###xml 112 116 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 278 282 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 357 361 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Immunohistochemistry demonstrates the presence of SV40 T antigen in SRC-1-/-/TRAMP and WT/TRAMP mouse prostate. SV40 T antigen immunostaining was uniform throughout the luminal epithelium of the prostate tissue. Prostate stromal cells, on the contrary, exhibited only scattered SV40 T antigen expression (Fig. 2B). Therefore, SRC-1 deficiency did not alter SV40 transgene expression.
###end p 23
###begin p 24
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 46 48 46 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 142 144 142 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 160 163 160 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 155 163 155 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
Protein levels of SRC-3 in SRC-1-/-/TRAMP and WT/TRAMP mouse prostates were examined by both immunohistochemistry and immunoblotting. In both WT/TRAMP and SRC-1-/-/TRAMP mice, SRC-3 immunoactivity was relatively low at 18 weeks of age in both normal and hyperplastic luminal epithelial cells, while at 24 weeks, SRC-3 immunoactivity was significantly increased in the prostate tumor cells (Fig. 4B). SRC-3 immunostaining specificity was validated by using SRC-3-null prostate as a negative control (Fig. 4B).
###end p 24
###begin p 25
###xml 92 94 92 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 211 214 211 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 206 214 206 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 281 283 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 489 491 489 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 507 510 507 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 502 510 502 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 555 558 555 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 550 558 550 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 598 600 598 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 565 569 <span type="species:ncbi:10090">mice</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
Unlike SRC-1, SRC-3 protein level increased progressively during prostate carcinogenesis in WT/TRAMP mice as assayed by immunoblotting (Fig. 4C). Interestingly, at 12 weeks of age SRC-3 in the prostates of SRC-1-/-/TRAMP mice was significantly higher than that in the prostates of WT/TRAMP mice, and this high level was maintained throughout the older age time points (Fig. 4C). These results demonstrate that SRC-3 is overexpressed during prostate carcinogenesis in the prostates of both WT/TRAMP and SRC-1-/-/TRAMP mice and SRC-3 overexpression in SRC-1-/-/TRAMP mice comes earlier compared with WT/TRAMP mice.
###end p 25
###begin p 26
###xml 106 109 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 175 178 175 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
We also performed immunoblotting analysis to examine SRC-3 protein levels in the prostates of WT and SRC-1-/- mice. We found no difference in SRC-3 levels between WT and SRC-1-/- prostates (Fig. 4D). These results suggest that SRC-1 ablation does not alter SRC-3 protein level in normal prostate and thus, SRC-3 overexpression is an event linked with prostate tumorigenesis.
###end p 26
###begin title 27
DISCUSSION
###end title 27
###begin p 28
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 436 439 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 431 439 431 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3<sup>-/-</sup></italic>
###xml 457 460 457 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 452 460 452 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 528 530 528 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 467 471 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
Certain steroid receptor coactivators such as SRC-3 are putative oncogenes in multiple cancers. Our laboratory demonstrated inactivation of SRC-3 could arrest prostate cancer at well-differentiated stages in TRAMP mice. Tumors in these mice neither progressed to poorly-differentiated stages nor metastasized. In the current study, we show that SRC-1 knockout does not arrest prostate cancer progression in TRAMP mice. Contrary to SRC-3-/-/TRAMP mice, SRC-1-/-/TRAMP mice develop prostate cancer at a similar rate and extent to WT/TRAMP mice. Both groups have similar tumor morphology and pattern of metastases.
###end p 28
###begin p 29
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 466 471 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 773 778 773 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 400 404 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 422 437 <span type="species:ncbi:10090">transgenic mice</span>
The failure of SRC-1 deletion to alter prostate cancer progression in the TRAMP model is at odds with clinical data correlating SRC-1 expression level and increased metastatic potential 18. One potential explanation for the contradiction is a requirement of SRC-1 overexpression for induction of more severe tumor phenotypes. Recently, we demonstrated that SRC-1 was upregulated in mammary tumors in MMTV-polyoma middle T transgenic mice, and that the overexpressed SRC-1 promoted tumor cell metastasis through increasing HER2 and colony-stimulating factor 1 (CSF-1) protein levels 21. In the present study, SRC-1 was not overexpressed and accordingly, its loss-of-function did not affect prostate tumor cell metastasis. These results support the notion that overexpressed SRC-1 may be still a dangerous factor in hormonally promoted cancers such as breast and prostate cancers.
###end p 29
###begin p 30
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 176 179 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 171 179 171 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 261 264 261 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 256 264 256 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1<sup>-/-</sup></italic>
###xml 275 277 275 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</italic>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
###xml 915 919 <span type="species:ncbi:10090">mice</span>
###xml 981 985 <span type="species:ncbi:10090">mice</span>
###xml 1064 1068 <span type="species:ncbi:10090">mice</span>
Further aiming to determine why our in vivo data in TRAMP mice did not correspond with cell line findings, we measured SRC-3 protein levels in advanced prostate tumors in SRC-1-/-/TRAMP mice. Interestingly, SRC-3 levels were significantly elevated in both SRC-1-/-/TRAMP and WT/TRAMP mice. In contrast, SRC-1 was expressed at relatively constant level in tumor cells throughout progression. These results suggest either a compensatory role for SRC-3 in SRC-1 mediated functions or a primacy of SRC-3 in mediating prostate tumorigenesis in the TRAMP model. The notion of partial redundancy between SRC-1 and SRC-3 in prostate carcinogenesis is consistent with multiple lines of evidence demonstrated in previous studies. First, both SRC-1 and SRC-3 interacted with multiple nuclear receptors and expression of either SRC-1 or SRC-3 could promote the receptor-mediated gene transcription. Second, although SRC-1 null mice had nearly normal development and growth and most SRC-3 null mice were viable and had normal life span, most of SRC-1 and SRC-3 double knockout mice were lethal before birth (reviewed in ref. 23).
###end p 30
###begin p 31
###xml 569 574 569 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 647 652 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
SRC-3 may act as a prostate cancer oncogene via several mechanisms. In the simplest case, it may directly coactivate AR-responsive transcriptional profiles in luminal epithelial cells. Alternatively, it may act outside of the luminal epithelial cell to stimulate the secretion of a diffusible growth factor. Such a mediator may be either a paracrine signal or an endocrine hormone, such as IGF-1, a molecule associated with prostate cancer progression. SRC-3 has been shown to maintain IGF-1 in circulation by regulating IGFBP-3 mRNA levels in multiple tissues. Global SRC-3 deletion decreases systemic IGF-1 levels and retards somatic growth 22. SRC-3-deficient mammary tumors also expressed lower IGF-1 mRNA 12. Finally, SRC-3 may be relevant in tumor cells not derived form the luminal epithelium. Precursor cell populations, capable of differentiation to multiple lineages within a given tumor have been identified in multiple cancers. SRC-3 may be relevant for the expansion or progression of a precursor population in the prostate that gives rise to tumor cells histologically resembling luminal epithelial cells. Identifying the role of SRC-3 in prostate cancer will require gene deletion targeted to luminal epithelial cells as well as other prostatic cell types.
###end p 31
###begin p 32
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3 </italic>
###xml 340 345 340 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-1</italic>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SRC-3</italic>
###xml 64 69 <span type="species:ncbi:10090">mouse</span>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 565 572 <span type="species:ncbi:9606">patient</span>
In conclusion, we demonstrate here that SRC-1 expression during mouse prostate carcinogenesis is relatively consistent and that SRC-1 deletion does not alter prostate tumor initiation, growth or progression in TRAMP mice. In contrast, SRC-3 is overexpressed during prostate carcinogenesis, indicating differential regulatory mechanisms for SRC-1 and SRC-3 promoters in the prostate tumor cells. The SRC-3 may play a dominant role versus SRC-1 in promoting prostate cancer progression in TRAMP mice. However, questions as to a role for increased SRC-1 in aggressive patient tumors indicate this coactivator warrant future assessment.
###end p 32
###begin p 33
###xml 50 54 <span type="species:ncbi:10090">mice</span>
We thank Dr. Norman Greenberg for providing TRAMP mice and Arthur Chung for initiating this project. This work is partially supported by National Health Institutes grants DK058242, CA112403 and CA119689.
###end p 33
###begin article-title 34
The changing face of prostate cancer
###end article-title 34
###begin article-title 35
Prostate cancer
###end article-title 35
###begin article-title 36
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
###end article-title 36
###begin article-title 37
Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions
###end article-title 37
###begin article-title 38
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene
###end article-title 38
###begin article-title 39
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP
###end article-title 39
###begin article-title 40
Partially redundant functions of SRC-1 and TIF2 in postnatal survival and male reproduction
###end article-title 40
###begin article-title 41
Regulation of somatic growth by the p160 coactivator p/CIP
###end article-title 41
###begin article-title 42
The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development
###end article-title 42
###begin article-title 43
SRC-3 is required for prostate cancer cell proliferation and survival
###end article-title 43
###begin article-title 44
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis
###end article-title 44
###begin article-title 45
###xml 153 157 <span type="species:ncbi:10090">mice</span>
AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice
###end article-title 45
###begin article-title 46
###xml 105 109 <span type="species:ncbi:10090">mice</span>
Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice
###end article-title 46
###begin article-title 47
Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway
###end article-title 47
###begin article-title 48
Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression
###end article-title 48
###begin article-title 49
The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression
###end article-title 49
###begin article-title 50
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy
###end article-title 50
###begin article-title 51
Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression
###end article-title 51
###begin article-title 52
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
Metastatic prostate cancer in a transgenic mouse
###end article-title 52
###begin article-title 53
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 139 144 <span type="species:ncbi:10090">Mouse</span>
###xml 155 160 <span type="species:ncbi:9606">Human</span>
Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee
###end article-title 53
###begin article-title 54
###xml 32 36 <span type="species:ncbi:10090">mice</span>
Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation
###end article-title 54
###begin article-title 55
Steroid receptor coactivator 3 maintains circulating insulin-like growth factor I (IGF-I) by controlling IGF-binding protein 3 expression
###end article-title 55
###begin article-title 56
Review of the in vivo functions of the p160 steroid receptor coactivator family
###end article-title 56
###begin p 57
###xml 30 33 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 479 482 477 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 393 397 <span type="species:ncbi:10090">mice</span>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
Prostate tumor growth in SRC-1-/-/TRAMP and WT/TRAMP mice. Body weight (panel A), genitourinary weight (panel B), seminal vesicle weight (panel C) and prostate weight (panel D) were recorded at sacrifice and the mean (+/- s.e.m.) relative organ weights are represented as a function of age and genotype. Relative weights are calculated by normalizing the organ weight to body weight. WT/TRAMP mice: 8 weeks, n=6; 12 weeks, n=10; 18 weeks, n=10; 24 weeks, n=9; 30weeks, n=7; SRC-1-/-/TRAMP mice: 8 weeks, n=3; 12 weeks, n=8; 18 weeks, n=10; 24 weeks, n=8; 30weeks, n=11.
###end p 57
###begin p 58
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A)</bold>
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 426 428 425 427 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B)</bold>
###xml 508 511 507 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 706 717 704 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Brown color</italic>
###xml 810 813 808 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 461 465 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
A) H&E stained histologic sections of the WT/TRAMP and SRC-1-/-/TRAMP prostate tissues at different tumorigenic stages (Pathologic grades: PIN, prostatic intraepithelial neoplasia; WD, well-differentiated adenocarcinoma; MD, moderately differentiated adenocarcinoma; PD, poorly differentiated adenocarcinoma; PHY, phylloides-like cancer). Images were taken at x200 magnification and the scale bars represent 50 mum in length. B) Immunohistochemical analysis of SV40 T antigen expression in WT/TRAMP and SRC-1-/-/TRAMP prostate tissues. Only dorsal lobes are shown here. The slides were counterstained with hematoxylin. Images were taken at x200 magnification and the scale bars represent 50 mum in length. Brown color, T antigen immunoreactivity. Note that T antigen expression levels are similar between SRC-1-/-/TRAMP and WT/TRAMP prostates.
###end p 58
###begin p 59
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A)</bold>
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 563 566 563 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 655 657 655 657 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B)</bold>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 727 731 <span type="species:ncbi:10090">mice</span>
###xml 815 819 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
A) The comparable weights of periaortic lymph nodes in WT/TRAMP and SRC-1-/-/TRAMP mice. The weights of periaortic lymph nodes were recorded and the relative periaortic lymph node weight was calculated. The box-and-whisker plot presents the distribution of relative lymph node weights. Whiskers represent all data analyzed, excluding outliers (represented by black dots), black line indicates median, and box represents 25% of data greater than and less than median. WT/TRAMP mice: 8 weeks, n=6; 12 weeks, n=10; 18 weeks, n=10; 24 weeks, n=9; 30 weeks, n=7; SRC-1-/-/TRAMP mice: 8 weeks, n=3; 12 weeks, n=8; 18 weeks, n=10; 24 weeks, n=8; 30 weeks, n=11. B) Histological analysis of the periaortic lymph nodes from 24-week-old mice. Upper panel was H&E stained sections while the lower panel was immunostained with SV40 T antigen antibody to identify the cancer cells with a prostatic origin (brown color). LNC, lymph node cells; MTC, metastatic tumor cells. Images were taken at x200 magnification and the scale bars represent 50 mum in length.
###end p 59
###begin p 60
###xml 104 106 104 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A)</bold>
###xml 139 150 139 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">brown color</italic>
###xml 190 193 190 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 245 247 245 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B)</bold>
###xml 280 291 280 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">brown color</italic>
###xml 331 334 331 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 405 408 405 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 538 540 537 539 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C)</bold>
###xml 631 634 630 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 704 705 703 704 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 777 780 776 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 802 805 801 804 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-/-</sup>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 415 420 <span type="species:ncbi:10090">mouse</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
###xml 806 810 <span type="species:ncbi:10090">mice</span>
Immunochemical analyses of SRC-1 and SRC-3 expression during prostate tumor initiation and progression. A) Immunohistochemistry for SRC-1 ,brown color, in the prostates of WT/TRAMP and SRC-1-/-/TRAMP (negative control) mice with indicated ages. B) Immunohistochemistry for SRC-3, brown color, in the prostates of WT/TRAMP and SRC-1-/-/TRAMP mice with indicated ages. A prostate sample of 24-week-old SRC-3-/-/TRAMP mouse was used as negative control. Images were taken at x200 magnification and the scale bars represent 50 mum in length. C) Western blot analyses of SRC-1 and SRC-3 in the prostates and tumors of WT/TRAMP and SRC-1-/-/TRAMP mice ages as indicated. Tubulin was used as a loading control. D) Western blot analyses of SRC-1 and SRC-3 in the prostates of WT (SRC-1+/+, non-TRAMP) and SRC-1-/- mice. beta-actin was used as a loading control. The stronger bands in panel D compared with those in panel C were because of a longer exposure time to the X-ray films in an independent experiment.
###end p 60

